Volanesorsen is a medication used to treat familial chylomicronemia syndrome (FCS). It is a rare, inherited disorder characterized by extreme levels of triglycerides in the blood, leading to organ damage, pancreatitis, and other serious complications. Volanesorsen is an antisense oligonucleotide (ASO) designed to reduce the production of an enzyme called apolipoprotein C-III (ApoC-III). ApoC-III is an important regulator of triglyceride levels. By reducing its production, Volanesorsen helps to lower triglyceride levels in patients with FCS.
Volanesorsen is a medication used to lower triglycerides, a type of fat, in the blood. It's specifically designed for a condition called familial chylomicronemia syndrome (FCS) in adults, where diet and other medications haven't been effective. It goes by the brand name Waylivra.
Here's a breakdown of how Volanesorsen works:
- Type of drug: Antisense oligonucleotide (ASO)
- Mechanism of action: Volanesorsen targets a specific protein called apolipoprotein C-III (apoC-III). It does this by attaching to the genetic material (mRNA) that instructs the body to make this protein. By attaching to this mRNA, Volanesorsen prevents the production of apoC-III. Normally, apoC-III slows down the breakdown of triglycerides. By reducing apoC-III, Volanesorsen helps the body remove triglycerides from the blood more efficiently.
Key points about Volanesorsen:
- Benefits: Lowers triglycerides, potentially reducing the risk of pancreatitis (inflammation of the pancreas) in FCS patients.
- Dosage: Given as a subcutaneous injection (under the skin) by a healthcare professional.
- Side effects: Reduced platelet levels (important for blood clotting), injection site reactions (pain, swelling, itching, bruising), increased LDL-C (another type of cholesterol), and potential for kidney or liver problems.
- Approval: Conditionally approved by the European Medicines Agency (EMA). It's not yet widely available everywhere.